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A B S T R A C T
L-Arginine is taken up via the cationic amino acid transporters (system y+/CATs) and system y+L in human
umbilical vein endothelial cells (HUVECs). L-Arginine is the substrate for endothelial NO synthase (eNOS) which
is activated by intracellular alkalization, but nothing is known regarding modulation of system y+/CATs and
system y+L activity, and eNOS activity by the pHi in HUVECs. We studied whether an acidic pHi modulates L-
arginine transport and eNOS activity in HUVECs. Cells loaded with a pH-sensitive probe were subjected to
0.1–20mmol/L NH4Cl pulse assay to generate pHi 7.13–6.55. Before pHi started to recover, L-arginine transport
(0–20 or 0–1000 μmol/L, 10 s, 37 °C) in the absence or presence of 200 μmol/L N-ethylmaleimide (NEM) (system
y+/CATs inhibitor) or 2 mmol/L L-leucine (systemy+L substrate) was measured. Protein abundance for eNOS
and serine1177 or threonine495 phosphorylated eNOS was determined. The results show that intracellular acid-
iﬁcation reduced system y+L but not system y+/CATs mediated L-arginine maximal transport capacity due to
reduced maximal velocity. Acidic pHi reduced NO synthesis and eNOS serine1177 phosphorylation. Thus, system
y+L activity is downregulated by an acidic pHi, a phenomenon that may result in reduced NO synthesis in
HUVECs.
1. Introduction
A variety of membrane transport systems removing metabolic sub-
strates from the extracellular medium are expressed in the foetopla-
cental endothelium [1–4]. The activity of some of these transport sys-
tems is modulated by changes in the extracellular (pHo) and
intracellular (pHi) pH [5,6]. The cationic amino acid L-arginine, the
substrate for the synthesis of nitric oxide (NO) via the endothelial NO
synthase (eNOS) [7,8], is taken up mainly by the cationic amino acid
transporters (CATs, also referred as system y+ or system y+/CATs)
family [4] and system y+L in human umbilical vein endothelial cells
(HUVECs) [2,9,10]. System y+/CATs corresponds to a family of ﬁve
proteins of which mainly the high aﬃnity (Km~ 100–250 μmol/L)
hCAT-1 and hCAT-2B isoforms are expressed in HUVECs [4,11]. System
y+L activity results from heterodimers formed by the interaction of the
heavy chain of the cell surface antigen 4F2 (4F2hc) with the light
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chains 4F2-lc2 (or y+LAT-1) or 4F2-lc3 (or y+LAT-2) [1,11–14].
System y+L activity accounts for L-arginine transport with a very high
aﬃnity (Km~ 1–20 μmol/L) and small and large neutral amino acids,
such as L-leucine, requiring extracellular sodium in HUVECs [4,9].
System y+/CATs and system y+L activity are reported as independent
of a change in pHo in mammalian cells [11,14]. However, there are no
reports addressing whether the activity of these membrane transport
systems is modulated by the pHi.
Increased L-arginine transport mediated by system y+/CAT-1 [15]
and system y+L [10] results in higher eNOS activity in HUVECs and
other cell types [16,17]. Interestingly, intracellular alkalization acti-
vates eNOS in HUVECs [18], human pulmonary arterial endothelial
cells (HPAECs) [19], and rat aorta endothelial cells (RAECs) [20].
However, it is unknown whether eNOS activation in response to a
change in the pHi leading to an alkaline or acidic intracellular en-
vironment associated with system y+/CATs and system y+L transport
activity in human endothelial cells. Intracellular alkalization due to
lower NHE1 activity reduced the transport of the endogenous nucleo-
side adenosine in HUVECs [6]. Since adenosine is a vasodilator in most
vascular beds including the foetoplacental circulation [21] via in-
creasing the L-arginine transport and NO synthesis in HUVECs [22], and
dysfunction of the foetoplacental vasculature is addressed as the cause
of altered umbilical vein blood ﬂow in growth restricted foetus [23,24],
it is likely that changes in the pHi in HUVECs alters the dynamics of NO-
dependent dilation mechanisms of the umbilical vein therefore limiting
the delivery of nutrients to the foetus [25]. This study aimed to char-
acterise the role of a change in pHi on L-arginine transport mediated via
system y+/CATs and system y+L and on NO synthesis in HUVECs.
2. Material and methods
2.1. Antibodies and materials
Primary monoclonal mouse anti-eNOS phosphorylated at serine1177,
anti-eNOS phosphorylated at threonine495, and anti-β-actin were from
Sigma Aldrich (St Louis, MO, USA). Primary monoclonal mouse anti-
total eNOS antibody and secondary horseradish peroxidase-conjugated
goat anti-mouse antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). For isolation of HUVECs from umbilical cords,
Collagenase Type II from Clostridium histolyticum (Boehringer,
Mannheim, FRG) was used. Medium M199, newborn (NBCS) and foetal
calf (FCS) sera, L-glutamine, and penicillin-streptomycin were from
Gibco Life Technologies (Carlsbad, CA, USA). L-[3H]Arginine and D-
[3H]mannitol were from NEN (Dreieich, FRG). NG-Nitro-L-arginine
methyl ester (L-NAME) was from Sigma Aldrich, Immobilon-P poly-
vinylidene diﬂuoride membranes from BioRad Laboratories
(Hertfordshire, UK), and the ﬂuorescent dye 4-amino-5-methylamino-
2′,7′-diﬂuoroﬂuorescein (DAF-FM) from Molecular Probes (Leiden, The
Netherlands).
2.2. Study group
This study included samples collected from 23 full-term normal
pregnancies from the Hospital Clínico UC-CHRISTUS (HCUC-C) in
Santiago de Chile and Clínica de la Mujer (CLM) in Antofagasta (Chile).
Pregnant women included in this study did not smoke or consume drugs
or alcohol and had no intrauterine infection or any other medical or
obstetrical complications. The ethnicity of patients involved in this
study was Hispanic. The investigation conforms to the principles out-
lined in the Declaration of Helsinki. Ethics Committee approvals from
the Faculty of Medicine of the Pontiﬁcia Universidad Católica de Chile
and CLM and informed written consent of patients were obtained.
2.3. Human placenta and umbilical cords
Placentas were collected at delivery on ice and transferred to the
laboratory until use 15–30min later. Middle sections of umbilical cords
(100–120mm length) were dissected into 200mL phosphate-buﬀered
saline (PBS) solution (mmol/L: 130 NaCl, 2.7 KCl, 0.8 Na2HPO4, 1.4
KH2PO4, pH 7.4, 4 °C) until use 6–12 h later for isolation of endothelial
cells [6,26].
2.4. Cell culture
This study was done in primary cultures of HUVECs from normal
pregnancies. The reason why selecting this type of cells is because (i)
they are from the umbilical vein which carries feotal blood after
crossing the placenta circulatory bed towards the foetus body with the
umbilical vein blood being rich in oxygen and nutrients and unloaded
of toxins and waste from the foetus circulation, (ii) umbilical vein blood
carries signalling molecules that are transferred from the mother
through the placenta into the foetal circulation, (iii) molecules syn-
thesised and released within the placenta tissue are available at the
umbilical vein blood thus transferring regulatory signals from the pla-
centa to this vessel by changing, for example, the oﬀering of nutrients
to the growing foetus, and (iv) HUVECs release extracellular vesicles,
including exosomes, that could potentially alter the downstream vas-
culature (i.e., the foetal circulation) altering or changing the function or
phenotype of the endothelium in the foetal vascular bed [27,28]. HU-
VECs were isolated by collagenase digestion (0.25mg/mL collagenase)
from umbilical cords obtained at delivery from normal pregnancies and
cultured (37 °C, 5% CO2) in 1% gelatin-coated Petri dishes (100mm
diameter) up to passage 3 in primary culture medium (PCM; M199
containing 5mmol/L D-glucose, 10% NBCS, 10% FCS, 3.2mmol/L L-
glutamine and 100 U/mL penicillin-streptomycin) as reported [6,26].
Sixteen hours prior experiments the incubation medium was changed to
M199 medium containing 0.25% NBCS and 0.25% FCS. Experiments
were in the absence or presence of NG-nitro-L-arginine methyl ester (L-
NAME, 100 μmol/L, NOS inhibitor) and cell viability was assayed using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide assay
(Sigma-Aldrich) as reported [6].
2.5. pHi measurement and recovery
Cells were loaded (10min, 37 °C) with the ﬂuorescent pH-sensitive
probe 2,7-bicarboxyethyl-5,6-carboxyﬂuorescein acetoxymethyl ester
(BCECF-AM, 12 μmol/L) as described [6]. Probe excess was removed
rinsing (×3) with control solution (CS) (mmol/L: NaCl 145, KCl 5,
NaH2PO4 1, Na2SO4 1, CaCl2 1.8, MgCl2 1, HEPES 30, D-glucose 5,
pH 7.4, 37 °C). Fluorescence ratios were registered every 0.5-seconds
interval. The pHi was estimated using standard calibration curves with
10 μmol/L nigericin and high-K+ in a calibrating solution (pH 6.2, 7.2,
8.2) as described [6]. The pHi recovery was examined by the NH4Cl
pulse technique [6]. After the basal pHi was stabilized (~3min) cells
were exposed (2min) to CS with 0.1, 1, or 20mmol/L NH4Cl (NH4Cl/
CS solution). Cells were then rinsed with NH4Cl-free CS, and cell via-
bility assayed as above.
2.6. Uptake of L-arginine
Since pHi recovery started after 25 s of removal of NH4Cl/CS,
transport assays in CS were performed at 20 s (37 °C). To identify the
involvement of system y+/CATs and system y+L on L-arginine trans-
port the cells were incubated with CS with or without 200 μmol/L N-
ethylmaleimide (NEM) (a general inhibitor of system y+/CATs) [1,11],
2 mmol/L L-leucine (a neutral amino acid that competes with L-arginine
for system y+L) [1,11], or NEM+ L-leucine as previously described
[10]. Overall uptake at 2 and 100 μmol/L L-arginine (6 μCi/mL L-[3H]
arginine, 20 s, 37 °C) for system y+L and system y+/CATs, respectively,
was measured in conﬂuent cells in CS as described [10,26]. The fraction
of uptake inhibited by NEM was considered as system y+/CATs medi-
ated, and the portion of uptake inhibited by L-leucine in cells
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coincubated with NEM to block system y+/CATs contribution was re-
garded as system y+L mediated [1,10,11].
2.7. Kinetics of L-arginine transport
Overall 0–20 μmol/L or 0–1000 μmol/L L-arginine transport (for
system y+L and system y+/CATs, respectively) was measured in CS as
above. Overall transport of L-arginine was deﬁned as the sum of a sa-
turable component plus a non-saturable, linear component of transport
in the ranges of L-arginine concentrations used in this study (hereafter
referred as a KD value deﬁned by m%[Arg], where m corresponds to
slopes of lineal phases of transport at a given L-arginine concentration
[Arg]) [26]. Cell monolayers were rinsed with ice-cold CS to terminate
tracer uptake.
The initial rate of transport (i.e., linear uptake up to 10 s) was de-
rived from the slope of the linear phases of L-arginine transport. Values
for transport were adjusted to the one phase exponential association
equation considering the least squares ﬁt:
= ⋅ −
− ⋅v V e(1 )i k tm ( )
where vi is initial velocity, Vm is mayor velocity at a given time (t) and L-
arginine concentration, and e and k are constants. Overall L-arginine
transport at initial rates was adjusted to the Michaelis-Menten hy-
perbola plus a nonsaturable, linear component (KD) as described [26].
The saturable transport of L-arginine was derived by subtracting the m
%[Arg] components from overall transport, and the transport kinetic
parameters maximal velocity (Vmax) and apparent Michaelis-Menten
constant (Km) of transport were calculated [26].
The relative contribution of system y+L and system y+/CATs (y+L/
y+F) to total transport (i.e., y+L plus y+/CATs mediated transport) in
cells non-treated (−NH4) or treated (+NH4) with NH4Cl was estimated
from Vmax/Km values by:
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where y+LVmax and y+LKm are kinetic parameters for system y+L-sa-
turable transport, and y+Vmax and y+Km for system y+/CATs saturable
transport.
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where −NH4Vmax and −NH4Km, or +NH4Vmax and +NH4Km are kinetic
parameters for transport in cells non-treated or treated with NH4Cl,
respectively [6].
The eﬃciency of the eﬀect of a change in the pHi (EpHi) on the
uptake at a ﬁxed concentration (UEpHi) or the maximal transport ca-
pacity (Vmax/KmEpHi) for a range of concentrations of L-arginine via
system y+/CATs and system y+L was estimated by:
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where uptake (U) at a given concentration of L-arginine (2 or 100 μmol/
L in this study) was measured in the absence (−NH4) or presence
(+NH4) of NH4Cl at basal pHi (−NH4pHi) or pHi in the presence of
NH4Cl (+NH4pHi). For a range of concentrations of L-arginine (0–20 or
0–1000 μmol/L in this study), the values for Vmax/Km were used. Each
transport assay was run in duplicate with transport activity expressed as
pmol/μg protein/min. Values for UEpHi and Vmax/KmEpHi are expressed as
a change in the pmol/μg protein/min relative to 1. Radioactivity in
0.5 N KCl cell digests was determined by liquid scintillation counting,
and uptake was corrected for D-[3H]mannitol disintegrations per minute
(d.p.m.) in the extracellular space [26].
2.8. NOS activity
NOS activity was assayed by quantiﬁcation of the intracellular
content of L-citrulline by high-performance liquid chromatography in
conﬂuent HUVECs in the absence or presence of 100 μmol/L L-NAME,
as reported [15,26].
2.9. Western blot for eNOS
Total protein was obtained from conﬂuent cells washed twice with
ice-cold PBS and harvested in 100 μL of lysis buﬀer composed by
63.7 mmol/L Tris/HCl (pH 6.8), 10% glycerol, 2% sodium dodecylsul-
phate, 1 mmol/L sodium orthovanadate, 50 mg/mL leupeptin, and 5%
2-mercaptoethanol, as described [26]. Cells were sonicated (6 cycles,
5 s, 100W, 4 °C), and total protein was separated by centrifugation
(14,000g, 15 min, 4 °C). Proteins (60 μg) were separated by poly-
acrylamide gel (10%) electrophoresis and transferred onto Immobilon-P
polyvinylidene diﬂuoride membranes. The proteins were then probed
against total eNOS (1:500 dilution, 12 h, 4 °C), eNOS phosphorylated at
serine1177 (P~Ser1177-eNOS, 1:1000 dilution, 12 h, 4 °C), eNOS phos-
phorylated at threonine495 (P~Thr495-eNOS, 1:1000 dilution, 12 h,
4 °C), and β-actin (1:3000, 1 h, room temperature). Membranes were
rinsed in Tris buﬀer saline-Tween (TBS-T) and incubated (1 h) in TBS-
T/0.2% BSA containing secondary horseradish peroxidase-conjugated
antibodies. Proteins were detected by enhanced chemiluminescence
(ﬁlm exposure time was 1min) in a ChemiDoc-It 510 Imagen System
(UVP, LCC Upland, CA, USA) and quantiﬁed by densitometry [26].
2.10. Statistical analysis
The sample size was estimated considering a power of 80% to detect
a diﬀerence between groups (by a two-sided alpha level of 0.05). Values
for clinical parameters are given as mean ± S.D. For in vitro assays the
values were mean ± S.E.M., where n indicates the number of diﬀerent
biological samples and corresponding cell cultures with 3–4 replicates
per experiment. Comparisons between two groups were performed
using Student's unpaired t-test and between more than two groups by
analysis of variance (ANOVA, two-ways). If the ANOVA demonstrated a
signiﬁcant interaction between variables, post hoc analyses were per-
formed by the multiple-comparison Bonferroni test. The statistical
software GraphPad InStat 3.1 and GraphPad Prism 7.0d (GraphPad
Software Inc., San Diego, CA, USA) was used for data analysis.
P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Study group
Pregnant women included in this study were with normal preg-
nancy, normotensive, normal fasting glycaemia at delivery, singleton,
and of similar age and height (Table 1). Weight and body mass index
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(BMI) at delivery were higher compared with the ﬁrst determination
early in pregnancy (9–16 weeks of gestation) where women were nor-
moweight (BMI < 25 kg/m2). The total gestational weight gain be-
tween early in pregnancy and delivery was 11.9 ± 0.7 kg with a BMI
variation of 0.6 kg/m2 reaching BMI values that were> 25–29.9 kg/
m2.
3.2. Basal pHi
Exposure of cells to 20mmol/L NH4Cl increased the pHi value, and
NH4Cl removal caused rapid acidiﬁcation (~1 s, pHi= 6.51 ± 0.04)
lasting for ~25 s before a signiﬁcant pHi recovery started reaching in-
itial pHi value in ~6min (Fig. 1A). The basal pHi value (7.19 ± 0.03)
was reduced by NH4Cl in a concentration-dependent manner (half-
maximal eﬀective concentration (EC50)= 1.29 ± 0.03mmol/L NH4Cl,
equivalent to pHi= 6.75 ± 0.02) (Fig. 1B), without altering the cell
survival (97–99% alive cells between 0.1 and 20mmol/L NH4Cl) (not
shown), conﬁrming previous observations in this cell type [6].
3.3. System y+/CATs and system y+L mediated uptake of L-arginine
In the absence of NH4Cl (i.e., at basal pHi), the overall uptake of
100 μmol/L L-arginine was inhibited mainly by NEM (69 ± 6%), with a
minor inhibition caused by L-leucine (25 ± 3%) but blocked in cells
coincubated with NEM+ L-leucine (Fig. 1C). In cells exposed to
20mmol/L NH4Cl and washed with CS solution (i.e., pHi ~6.5), the
overall uptake was reduced compared with cells in the absence of
NH4Cl in a proportion (0.14 ± 0.02 pmol/μg protein/min) that was
similar in cells incubated with L-leucine in the absence of NH4Cl
(0.15 ± 0.06 pmol/μg protein/min). In the presence of NH4Cl, the
uptake of L-arginine was inhibited by NEM or NEM+ L-leucine in a
similar proportion (0.42 ± 0.02 and 0.44 ± 0.02 pmol/μg protein/
min, respectively), but NH4Cl did not alter the uptake of L-arginine
inhibited by L-leucine in the absence of this salt. Uptake of L-arginine
mediated by system y+/CATs predominates over a minor contribution
of system y+L at 100 μmol/L L-arginine (Fig. 1D).
The overall uptake at 2 μmol/L L-arginine (0.17 ± 0.05 pmol/
μg protein/min) in the absence of NH4Cl was lower (67 ± 3%) com-
pared with 100 μmol/L L-arginine (Fig. 1E). The uptake detected at this
concentration of L-arginine was similar to the fraction of uptake in-
hibited by L-leucine in 100 μmol/L L-arginine (0.15 ± 0.06 pmol/
μg protein/min). Overall uptake was unaltered by NEM but blocked by
L-leucine or NEM+ L-leucine. In the presence of NH4Cl the 2 μmol/L L-
arginine uptake was abolished in all experimental conditions. Uptake of
L-arginine mediated by system y+L accounted for 2 μmol/L L-arginine in
HUVECs (Fig. 1F). NH4Cl did not alter 100 or 2 μmol/L L-arginine up-
take via system y+/CATs. However, the system y+L activity in the
presence of NH4Cl at these two concentrations of L-arginine was abol-
ished.
3.4. pHi-dependent uptake of L-arginine via system y+L/CATs and system
y+L
Overall uptake of 100 μmol/L L-arginine was unaltered by 0.1 or
1mmol/L NH4Cl in the absence of NEM and by 0.1mmol/L NH4Cl in
the presence of NEM, but reduced by 20mmol/L NH4Cl in the absence
or presence of NEM (Fig. 2A). Incubation of cells with NEM resulted in a
NH4Cl concentration-dependent inhibition of uptake
(EC50= 0.32 ± 0.04mmol/L NH4Cl). Overall uptake of 2 μmol/L L-
arginine in the presence of NEM was inhibited by NH4Cl
(EC50= 0.31 ± 0.0.3 mmol/L NH4Cl), but uptake was unaltered in
cells incubated with NEM+ L-leucine (Fig. 2B). Uptake mediated by
system y+/CATs was not signiﬁcantly altered by NH4Cl (Fig. 2C) and
independent of the resulting pHi (Fig. 2D). However, uptake mediated
by system y+L was reduced in a concentration-dependent manner by
NH4Cl (EC50= 0.29 ± 0.03mmol/L NH4Cl) and the resulting acidic
pHi (EC50= 6.89 ± 0.11 pHi).
The eﬃciency of inhibition of a change in pHi (ΔpHi) on 2 μmol/L L-
arginine uptake (UEpHi) mediated via system y+L was higher at the
smaller variation of pHi (ΔpHi 0.06 in this study) and less pronounced
but reaching comparable values at higher variations of pHi (ΔpHi 0.38
and 0.69 in this study) from the basal pHi value in HUVECs (Fig. 2E).
However, the UEpHi for uptake via system y+/CATs was unaltered by
the pHi. The UEpHi for system y+L compared with system y+/CATs
mediated uptake was higher at pHi 7.19 compared with uptake at pHi
6.81 or 6.5 (Fig. 2F).
3.5. pHi-dependent system y+/CATs and system y+L transport kinetics
In the absence of NH4Cl, the overall transport of L-arginine in the
range of 0–1000 μmol/L was semi-saturable, inhibited mainly by NEM
but marginally inhibited by L-leucine, and blocked by NEM+ L-leucine
(not shown) as previously reported [10]. The derived transport ob-
tained after subtracting the linear, non-saturable component from
overall transport (i.e., KD), was saturable in all experimental conditions
and adjusted to a ﬁrst order linear regression in Eadie-Hofstee plots as
reported [10,15]. Incubation of cells with increasing concentrations of
NH4Cl did not alter the KD for overall transport and the Vmax, Km, or
Vmax/Km for saturable transport in this range of L-arginine concentra-
tions (Table 2).
Overall transport of L-arginine in the range of 0–20 μmol/L L-argi-
nine was semi-saturable, unaltered by NEM but abolished by L-leucine
or NEM+ L-leucine (not shown) as previously reported [10]. The de-
rived saturable L-arginine transport was unaﬀected by NEM but blocked
by L-leucine and NEM+ L-leucine (Fig. 3A). A ﬁrst-degree regression
line well ﬁtted saturable transport at diﬀerent pHi values in Eadie-
Hofstee plots (Fig. 3B). Increasing concentrations of NH4Cl did not alter
the KD for overall transport but reduced the Vmax (Table 2) and Vmax/Km
(Fig. 3C) without changing the Km for saturable transport.
The eﬃciency of inhibition of a given ΔpHi in 0–20 μmol/L L-argi-
nine transport kinetic parameters (Vmax/KmEpHi) for system y+L was also
Table 1
Clinical variables in pregnant women and newborns.
Mother
Age (years) 31.4 ± 3.9 (26.2–37.5)
Height (cm) 161.7 ± 3.9 (154.1–163.2)
Weight (kg)
9–16weeks of gestation 56.2 ± 3.4 (54.6–59.5)
Delivery 68.1 ± 3.9 (64.2–69.1)⁎
BMI (kg/m2)
9–16weeks of gestation 21.5 ± 1.7 (20.1–22.3)
Delivery 26.1 ± 0.9 (25.1–29.3)⁎
Mean arterial pressure (mmHg)
9–16weeks of gestation 77.1 ± 3.5 (75.5–79.2)
Delivery 81.7 ± 6.1 (79.8–89.2)
Glycemia fasting (mg/dL) 83.1 ± 6.9 (74.9–89.5)
OGTT (mg/dL)
Glycemia basal 82.7 ± 3.2 (78.2–85.3)
Glycemia 2 h after glucose 83.3 ± 4.1 (82.1–89.0)
Newborn
Sex (female/male) 13/10
Gestational age (weeks) 38.3 ± 0.7 (38.0–38.9)
Birth weight (g) 3182 ± 210 (3051–3346)
Height (cm) 49.7 ± 1.2 (48.1–52.2)
Ponderal index (g/cm3× 100) 2.59 ± 0.12 (2.12–2.63)
Women that coursed with normal pregnancies (n=23) were included in this study.
Weight, body mass index (BMI), and blood pressure were determined at the ﬁrst interview
with the obstetrician (9–16weeks of pregnancy) and at delivery. BMI was calculated by
weight in kilograms divided by the square of the height in meters. Ponderal index was
calculated by weight in grams divided by the cube of height in centimeters multiplied by
100. Oral glucose tolerance test (OGTT) was measured at the 1st trimester of pregnancy in
all women with a normal glycaemia (see Material and methods section). Values are
mean ± S.D. plus range in brackets.
⁎ P < 0.05 versus corresponding values at 9–16weeks of gestation.
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higher at the smaller variation of pHi (ΔpHi 0.06) and less pronounced
but reaching comparable values at higher variations of pHi (ΔpHi 0.38
and 0.69) from the basal pHi (Fig. 3D). The pHi unaltered the Vmax/
KmEpHi for transport via system y+/CATs. The Vmax/KmEpHi for system
y+L compared with system y+/CATs mediated transport was higher
at all pHi used in this study (Fig. 3E).
3.6. NOS activity
In the absence of NH4Cl, total synthesis of L-citrulline in cells in-
cubated with 100 μmol/L L-arginine was partially reduced by NEM and
L-leucine but abolished by NEM+ L-leucine (Fig. 4A). NH4Cl similarly
inhibited L-citrulline synthesis in the absence or presence of L-leucine
Fig. 1. Eﬀect of cell pHi on L-arginine uptake in HUVECs. A. Cells were preloaded with BCECF-AM and transferred into a spectroﬂuorometer. After basal pHi stabilisation, the cells were
exposed (2min) to a control solution containing 20mmol/L NH4Cl (+NH4Cl). Cells were then rinsed with a NH4Cl-free solution (−NH4Cl) and left in this medium for pHi recovery (see
Material and methods section). A typical record is shown. The insert indicates the data for the ﬁrst 55 s after removal of NH4Cl. The grey area indicates the time (10 s) used for overall
uptake of 2 or 100 μmol/L L-arginine (6 μCi/mL L-[3H]arginine, 37 °C). B. pHi values for cells exposed to a Na+-free solution without (0) or with NH4Cl. C. Overall 100 μmol/L L-arginine
uptake in +NH4Cl or−NH4Cl solution in the absence (−) or presence (+) of N-ethylmaleimide (NEM) or L-leucine. D. L-Arginine uptake mediated via system y+/CATs derived from data
in C. E. Overall 2 μmol/L L-arginine uptake as in C. F. L-Arginine uptake mediated via system y+L derived from data in E. In B, *P < 0.05 versus without or with 0.1mmol/L NH4Cl. In C,
*P < 0.05 versus all other values, †P < 0.05 versus corresponding values in the presence of NEM or NEM+ L-leucine. ‡P < 0.05 versus values in−NH4Cl in the presence of NEM. In D,
*P < 0.03 versus corresponding values in 2 μmol/L L-arginine. In E, *P < 0.03 versus all other values except for−NH4Cl in the presence of NEM. In F, *P < 0.03 versus corresponding
values in +NH4Cl. Values are mean ± S.E.M. (n=18).
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but blocked by NEM and NEM+ L-leucine. Incubation of cells with L-
NAME blocked L-citrulline synthesis in all experimental conditions. The
NOS-dependent fraction of synthesis of L-citrulline was reduced by NEM
or L-leucine but abolished by NEM+ L-leucine (Fig. 4C). In the presence
of NH4Cl, NOS-dependent L-citrulline synthesis was decreased partially
reaching similar values to those in the presence of L-leucine. However,
it was abolished in the presence of NEM or NEM+ L-leucine.
In the absence of NH4Cl, total synthesis of L-citrulline in cells in-
cubated with 2 μmol/L L-arginine was unaltered by NEM but abolished
by L-leucine and NEM+ L-leucine (Fig. 4B). NH4Cl and L-NAME also
abolished L-citrulline synthesis. The NOS-dependent synthesis of L-ci-
trulline in the absence of NH4Cl was unaltered by NEM but blocked by
Fig. 2. Eﬀect of pHi on L-arginine uptake in HUVECs. A. L-Arginine (100 μmol/L) uptake (6 μCi/mL L-[3H]arginine, 10 s, 37 °C) in primary cultures of HUVECs non-treated (0) or treated
with increasing concentrations of NH4Cl as described in Materials and methods. Cells were in the absence (Control) or presence of 200 μmol/L N-ethylmaleimide (NEM). B, L-Arginine
(2 μmol/L) uptake as in A in the presence of 200 μmol/L NEM (i.e., Control for this concentration of L-arginine) or NEM plus 2mmol/L L-leucine (NEM+ L-leucine). C. L-Arginine uptake
via system y+/CATs and system y+L derived from data in A and B, respectively, in the absence of presence of NH4Cl. D. L-Arginine uptake against pHi values in cells as in C. E. Eﬃciency
of a change in the pHi (ΔpHi) on the uptake of L-arginine (UEpHi) via system y+/CAT and system y+L from data in D. Values for UEpHi are expressed as a change in the pmol/μg protein/
min relative to 1 (see Material and methods section). F. Relative UEpHi for system y+/CAT and system y+L from data in E. In A, B, and C, *P < 0.05 versus corresponding values without
NH4Cl. In D, *P < 0.05 versus corresponding values at pHi 7.13 and pHi 7.19. In E, *P < 0.03 versus all other corresponding values, †P < 0.05 versus corresponding value at
ΔpHi= 0.69 pHi units. In F, *P < 0.03 versus all other values, †P < 0.05 versus values at pHi= 6.5. Values are mean ± S.E.M. (n=19).
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L-leucine and NEM+ L-leucine (Fig. 4D). NH4Cl reduced, but NEM, L-
leucine, and NEM+ L-leucine blocked the NOS-dependent synthesis of
L-citrulline.
3.7. eNOS expression and activation
Total eNOS protein abundance was unaltered by an acidic pHi
(Fig. 5A,B). Phosphorylation of eNOS at Ser1177 was reduced in a pHi-
dependent manner (EC50= 0.77 ± 0.03 pHi) (Fig. 5C); however,
eNOS phosphorylation at Thr495 was unaltered by acidic pHi (Fig. 5D).
4. Discussion
This study shows that pHi is a factor that modulates the L-arginine
transport in primary cultured HUVECs from normal pregnancies.
Intracellular acidiﬁcation causes a reduction in the L-arginine transport
via system y+L but not via system y+/CATs, and in the activity of eNOS
due to lower activator phosphorylation in Ser1177 at this enzyme. Since
Table 2
Eﬀect of intracellular pH on the kinetic parameters for L-arginine transport in HUVECs.
Saturable transport Overall transport
Vmax
(pmol/μg protein/min)
Km
(μmol/L)
Vmax/Km
(pmol/μg protein/min/(μmol/L))
KD
(pmol/μg protein/min/(μmol/L))
vi
(pmol/μg protein/0.5 s)
System y+/CATs
Without NH4Cl pHi 7.19 0.60 ± 0.18 79 ± 49 0.008 ± 0.004 0.0025 ± 0.0002 0.00279 ± 0.00022
With NH4Cl (mmol/L)
0.1 pHi 7.13 0.61 ± 0.11 97 ± 29 0.006 ± 0.002 0.0022 ± 0.0002 0.00258 ± 0.00022
1 pHi 6.89 0.58 ± 0.12 73 ± 31 0.008 ± 0.003 0.0022 ± 0.0002 0.00279 ± 0.00018
20 pHi 6.50 0.53 ± 0.08 84 ± 32 0.006 ± 0.002 0.0023 ± 0.0003 0.00240 ± 0.00021
System y+L
Without NH4Cl pHi 7.19 0.38 ± 0.11 1.98 ± 1.06 0.192 ± 0.079 0.0492 ± 0.0048 0.00159 ± 0.00019
With NH4Cl (mmol/L)
0.1 pHi 7.13 0.33 ± 0.08 2.01 ± 0.91 0.164 ± 0.057 0.0511 ± 0.0041 0.00137 ± 0.00019
1 pHi 6.89 0.21 ± 0.09* 2.12 ± 0.99 0.099 ± 0.044* 0.0488 ± 0.0052 0.00084 ± 0.00011*
20 pHi 6.50 0.04 ± 0.02 1.99 ± 0.12 0.020 ± 0.003 0.0479 ± 0.0048 0.00017 ± 0.00008
Transport of L-arginine (20 s, 37 °C) was measured in HUVECs from normal pregnancies. Transport assays were done in cells not treated (Without NH4Cl) or treated (With NH4Cl) in a
NH4Cl-acid pulse as described in Materials and methods. The resulting intracellular pH (pHi) values are indicated. Maximal velocity (Vmax) and apparent Michaelis-Menten constant (Km)
of saturable transport in the range of 0–20 μmol/L (for system y+L) or 0–1000 (for system y+/CATs) L-arginine were calculated assuming a single Michaelis-Menten hyperbola. Vmax/Km
represents maximal L-arginine transport capacity. The lineal phase of overall transport of L-arginine (KD) was obtained from transport data ﬁtted to a Michaelis-Menten equation increased
in a lineal component. Initial velocity (vi) was calculated for 0.5 s with 100 or 2 μmol/L L-arginine transport. All values for Vmax, Km, and vi for system y+L are lower (P < 0.05) and
values for Vmax/Km and KD were higher (P < 0.05) than corresponding values for system y+/CATs. *P < 0.05 versus all other corresponding values for System y+L. Values are
mean ± S.E.M. (n=19).
Fig. 3. Eﬀect of NH4Cl on L-arginine saturable transport in HUVECs. A. Saturable L-arginine transport (6 μCi/mL L-[3H]arginine, 10 s, 37 °C) was measured in primary cultures of HUVECs
non-treated (Control, i.e., pHi 7.19) or treated with 0.1, 1, or 20mmol/L NH4Cl reaching pHi 7.13, 6.81, or 6.5, respectively (see Material and methods section). Cells at pHi 7.19 were in
the absence or presence of 200 μmol/L N-ethylmaleimide (NEM) or NEM plus 2mmol/L L-leucine (NEM+ L-leucine). Cells in pHi 7.13, 6.81, or 6.5 were exposed to NEM. B. Eadie-
Hofstee plots for transport data in cells in the presence of NEM as in A. C. Maximal transport capacity (Vmax/Km) for systems y+/CATs and system y+L from data in A (see also Table 2). D.
The eﬃciency of a change in the pHi (ΔpHi) on maximal transport capacity for L-arginine (Vmax/KmEpHi) via system y+/CATs and system y+L from data in A. Values for Vmax/KmEpHi are
expressed as a change in the pmol/μg protein/min relative to 1 (see Material and methods section). E. Relative Vmax/KmEpHi for system y+/CAT and system y+L from data in D. In C,
*P < 0.05 versus corresponding values at pHi 7.13 and 7.19. In D, *P < 0.05 versus all other values. Values are mean ± S.E.M. (n=19).
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NO is involved in a broader range of biological eﬀects other than reg-
ulation of vascular tone, intracellular acidiﬁcation may have signiﬁcant
implications in diseases associated with endothelial dysfunction, such
as gestational diabetes mellitus and cancer, where the pHo and pHi are
altered [6,27–29].
HUVECs show a pHi ~ 7.19 as previously reported (pHi ~ 7.21)
[6,30,31], and is close to the pH reported in the human umbilical vein
blood (pH~ 7.35) [25,32–34]. Intracellular acidiﬁcation down-
regulates the transport activity of the human equilibrative nucleoside
transporters 1 and 2 in HUVECs [6], and Na+/H+ exchanger 1 in
human lymphoblasts [34] and the human colonic carcinoma T84 cell
line [35]. Since overall L-arginine transport was reduced as the pHi
changed to acidic in HUVECs, L-arginine transport mechanisms are re-
sponsive to a change in the pHi in this cell type. Inhibition by the acidic
pHi was partial and similar to that induced by L-leucine at basal or
acidic pHi in the presence of 100 μmol/L L-arginine. Considering the
apparent Km for L-arginine uptake via hCAT-1 (Km~ 120 μmol/L) and
hCAT-2B (Km~250 μmol/L) in this cell type [1,2,36] it is likely that
these isoforms were involved in this phenomenon. L-Arginine transport
via system y+/CATs is independent of pHo in mammalian cells
[2,11,37]. However, there are no studies addressing modulation of L-
arginine transport by pHi in endothelium or other cell types
[2,11,34,37]. Our results suggest that system y+/CATs activity (likely
hCAT-1 and hCAT-2B) is independent of intracellular acidiﬁcation up to
ΔpHi ~ 0.69 from the basal pHi since the eﬀect of the ΔpHi on
100 μmol/L L-arginine uptake (UEpHi 0.022 ± 0.012, range 0.01–0.06)
or the Vmax/Km for transport (Vmax/KmEpHi 0.0037 ± 0.0011, range
0.002–0.005) of this amino acid was unaltered.
Uptake of L-arginine is also mediated by system y+L in HUVECs
[9,10]. Uptake of 2 μmol/L L-arginine was almost exclusively mediated
via system y+L meanwhile at higher levels (100 μmol/L) transport was
via system y+/CATs and system y+L. The results show that system y+L
transport activity was sensitive to acidic pHi in HUVECs [34,38], an
eﬀect that was higher at smaller changes from the basal pHi. Thus,
system y+L seems more eﬃciently modulated by a discrete change in
pHi (ΔpHi 0.06 in this study) from the physiological pHi in HUVECs.
Similar changes were seen with 2 μmol/L or a broader concentration of
L-arginine (UEpHi/Vmax/KmEpHi ~ 0.8). Thus, pHi modulation of system
y+L activity results from changing the Vmax/Km for system y+L, an
eﬀect that results from reduced Vmax. Several possibilities may explain
this ﬁnding, i.e., (i) reduced number of transporters available at the
plasma membrane due to lower expression or recycling with no change
in their transport capacity, (ii) decreased transport capacity of a ﬁxed
number of membrane transporters, or (iii) both phenomena. Since pHi
eﬀect on transport was assayed for 15 s and system y+L half-life is most
likely unaltered at this incubation time, the reduced L-arginine trans-
port may result from a lower activity rather than expression of system
y+L in HUVECs.
An increase in the activity of system y+L associated with a higher
synthesis of NO in HUVECs [1,10], human platelets [16,17], and rat
cortical astrocytes [39]. Also, since system y+L may be located close to
eNOS in the plasma membrane [2], the pHi-decreased system y+L
transport activity may result in lower eNOS activity in HUVECs. Our
results show that L-NAME–inhibited L-citrulline formation from L-argi-
nine (index of NOS activity) [8] was lower at acidic pHi. This phe-
nomenon was associated with a reduced activity of system y+L, but not
system y+/CATs and abolished at 2 μmol/L but partially reduced at
100 μmol/L L-arginine. Interestingly, eNOS activity seems linked to
system y+/CATs (particularly hCAT-1 and hCAT-2) in HUVECs
[2,40–42]. However, an intracellular L-arginine pool not fed from this
amino acid extracellular content is also a supplying source for eNOS in
this cell type [40,42]. Thus, CATs transport activity could be unaltered,
up or downregulated and these changes will not necessarily lead to
parallel changes in NOS activity. Indeed, HUVECs from late-onset
Fig. 4. pHi dependency of NOS activity in HUVECs. A. Intracellular L-citrulline level was determined by H.P.L.C. in primary cultures of HUVECs not treated (−NH4Cl) or treated
(+NH4Cl) with 20mmol/L NH4Cl in the absence or presence of 100 μmol/L NG-nitro- L-arginine methyl ester (L-NAME) as described in Material and Methods section. Assays were in cells
in 100 μmol/L L-arginine in the absence or presence of 200 μmol/L N-ethylmaleimide (NEM) or NEM plus 2mmol/L L-leucine (NEM+ L-leucine). B. The intracellular L-citrulline level in
HUVECs in 2 μmol/L L-arginine as in A. C. Nitric oxide synthase (NOS) activity-dependent L-citrulline synthesis derived from data in A. D. Nitric oxide synthase (NOS) activity-dependent
L-citrulline synthesis derived from data in B. In A, *P < 0.05 versus all other values, †P < 0.05 versus corresponding values except in the presence of L-leucine. ‡P < 0.05 versus all
other corresponding values. All values in the presence of L-NAME are signiﬁcantly diﬀerent (P < 0.03) from values in the absence of this inhibitor. In B, *P < 0.03 versus all other
values. In C, *P < 0.05 versus all other values, †P < 0.05 versus all other corresponding values except in the presence of L-leucine, ‡P < 0.05 versus all other corresponding values
except in the presence of NEM+ L-leucine, §P < 0.03 versus corresponding values in the presence of L-leucine. In D, *P < 0.05 versus all other values except for−NH4Cl in the presence
of NEM, †P < 0.05 versus all other corresponding values, ‡P < 0.05 versus corresponding values in −NH4Cl. Values are mean ± S.E.M. (n=19).
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preeclampsia show increased hCAT-1–mediated L-arginine transport
but reduced eNOS activity [43,44]. Potential explanations for this
phenomenon include the possibility that system y+/CATs activity may
deliver L-arginine for NOS activity and NO generation, arginase activity
for the synthesis of polyamines, or for protein synthesis [43,44].
The reduced NOS activity seen in HUVECs in an acidic pHi was
likely due to lower eNOS activation since its lower activator phos-
phorylation at serine1177 [8,18,26] instead of an increased inhibitory
phosphorylation of threonine497 [8,18,26]. Since intracellular alkali-
zation activates eNOS in HUVECs [18], and other endothelium in-
cluding human pulmonary aortic [19] and rat aortic [20] endothelial
cells, intracellular acidiﬁcation may result in reduced NO synthesis in
HUVECs. Interestingly, a change in pHi from 7.5 to ~6.5 resulted in a
more signiﬁcant reduction of NOS activity compared with a pHi shift
from 6.5 to 5.5 [18], thus complementing similar ﬁndings for system
y+L activity in HUVECs. Thus, a change in pHi causing intracellular
acidiﬁcation is a phenomenon involved in downregulation of the
system y+L/eNOS activity in HUVECs. The possibility that intracellular
acidiﬁcation inhibited NOS was not related to L-arginine uptake is un-
likely since incubation of cells with NEM+ L-leucine abolished L-argi-
nine uptake and NO synthesis. This proposal is supported by studies in
rat astrocytes knockdown for system y+/LAT-2 expression where
system y+L activity and NO generation was reduced [39].
In summary, intracellular acidiﬁcation results in reduced membrane
transport of L-arginine mediated via system y+L but not via system y+/
CATs in HUVECs (see Fig. 6). Diminished transport resulted from lower
maximal transport capacity due to reduced Vmax without signiﬁcant
alterations in the apparent Km for transport. Therefore, an acidic pHi
seems not to alter the intrinsic properties of system y+L but the activity
of membrane transporters in HUVECs. Interestingly, the pHi sensitivity
of L-arginine transport was higher as smaller the change in the pHi from
the basal pHi in this cell type. Additionally, intracellular acidiﬁcation
also reduced the synthesis of NO and activator phosphorylation of
eNOS, which seems to result from reduced system y+L activity and
lower activation of eNOS. Interestingly, preliminary results show that
basal pHi is alkaline in HUVECs exposed to an A2A adenosine receptors
antagonist (L Sobrevia, unpublished), suggesting that basal pHi is po-
tentially maintained by activation of this type of adenosine receptors in
HUVECs. We hypothesise that changing the pHi into an acidic in-
tracellular environment is a phenomenon likely involved in the lower
adenosine-mediated relaxation of foetoplacental vasculature via redu-
cing the endothelial system y+L/eNOS activity as seen in diseases of
pregnancy such as preeclampsia [44,45], obesity [46,47], or gestational
diabetes mellitus [21,27,28].
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Fig. 5. pHi dependency of eNOS expression and phosphorylation in HUVECs. A. Western blot for total (Total eNOS) or phosphorylated at Serine1177 (P-Ser1177eNOS) or Threonine495 (P-
Thr495eNOS) eNOS protein in primary cultures of HUVECs non-treated (Control, i.e., pHi= 7.19) or treated with 0.1, 1, or 20mmol/L NH4Cl reaching pHi 7.13, 6.81, or 6.5, respectively
(see Material and methods section). β-Actin is the loading control. Total eNOS/β-actin (B), P-Ser1177eNOS/Total eNOS (C) or P-Thr495eNOS/Total eNOS (C) protein ratios from cells as in
A. *P < 0.05 versus values at pHi 7.19 and 7.13. Values are mean ± S.E.M. (n=19).
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